Checking in with the co-founders of Amylyx Pharmaceuticals, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year
- Jun 25, 2025
- 1 min read
Josh Cohen and Justin Klee walk us through the lead program, avexitide, which is a GLP-1 antagonist and is currently in a pivotal study that will read out in 1H26. Plus, updates on AMX0035 in Wolfram Syndrome and Progressive Supranuclear Palsy, and an ALS program targeting calpain-2 that will have initial data later this year.
.png){kind=logo}